Suppr超能文献

使用各种影像学方法评估右心室大小和功能终点的肺动脉高压药物试验的样本量和成本分析。

Sample size and cost analysis for pulmonary arterial hypertension drug trials using various imaging modalities to assess right ventricular size and function end points.

机构信息

Section of Cardiology, Department of Medicine, and Department of Radiology, University of Chicago, IL.

出版信息

Circ Cardiovasc Imaging. 2014 Jan;7(1):115-24. doi: 10.1161/CIRCIMAGING.113.000932. Epub 2013 Nov 5.

Abstract

BACKGROUND

Placebo-controlled trials for pulmonary arterial hypertension are no longer acceptable because new therapies must show clinically significant effects on top of standard treatment. The purpose of this study was to estimate sample sizes and imaging costs for the planning of a hypothetical pulmonary arterial hypertension drug trial using imaging to detect changes in right ventricular size and function in response to combined therapy.

METHODS AND RESULTS

Same-day cardiovascular MR (CMR) and 2-dimensional (2D) and 3D transthoracic echocardiography (2DTTE and 3DTTE) were performed in 22 patients with pulmonary arterial hypertension (54±13 years of age) twice, 6 months apart. Short-axis CMR cines and full-volume 3DTTE data sets of the right ventricle were used to measure end-diastolic volume and ejection fraction. Fractional area change was obtained from 2DTTE. Sample size calculations used a 2-sample t test model incorporating differences between baseline and 6-month measurements. Cost estimates were made using the Medicare fee schedule. No significant differences were noted between baseline and follow-up measurements. Large SDs reflected variable progression of disease in individual patients on standard therapy and measurement variability. These sources of variability resulted in intertechnique differences in sample sizes: to detect a change of 5% to 15% in 3DTTE-derived right ventricular ejection fraction and fractional area change or change of 15 to 30 mL in 3DTTE right ventricular end-diastolic volume; sample sizes were 2× to 2.5× those required by CMR. As a result, the total cost of a trial using complete TTE was greater than CMR, which was greater than limited TTE.

CONCLUSIONS

Because of lower measurement variability, CMR is more cost saving in pulmonary arterial hypertension drug trials than echocardiography, unless limited TTE is used.

摘要

背景

由于新疗法必须在标准治疗的基础上显示出临床显著效果,因此不再接受肺动脉高压的安慰剂对照试验。本研究的目的是估计使用影像学检测右心室大小和功能变化对联合治疗反应的假设肺动脉高压药物试验的样本量和影像学成本。

方法和结果

在 22 例肺动脉高压患者(54±13 岁)中,在 6 个月的时间间隔内进行了两次同日心血管磁共振(CMR)和 2 维和 3 维经胸超声心动图(2DTTE 和 3DTTE)检查。使用短轴 CMR 电影和右心室全容积 3DTTE 数据集测量舒张末期容积和射血分数。从 2DTTE 获得分数区域变化。样本量计算使用包含基线和 6 个月测量值之间差异的 2 样本 t 检验模型。成本估算使用医疗保险费用表。基线和随访测量值之间没有显著差异。大标准差反映了标准治疗和测量变异性个体患者疾病的不同进展。这些变异性来源导致了不同技术之间的样本量差异:为了检测 3DTTE 衍生的右心室射血分数和分数区域变化的 5%至 15%的变化或 3DTTE 右心室舒张末期容积的 15%至 30%的变化;样本量是 CMR 所需样本量的 2 倍至 2.5 倍。因此,使用完整 TTE 的试验总成本高于 CMR,而 CMR 又高于有限 TTE。

结论

由于测量变异性较低,CMR 在肺动脉高压药物试验中比超声心动图更具成本效益,除非使用有限 TTE。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验